Account
News

PMA Insights: Week 7

17/02/2023
  • CEPs Annual Report indicates reduced time to market access
  • The FDA’s Biosimilar User Fee Amendments III (BsUFA III)
15022023-News-Digest-Wk-7Download

Author:

Amy Rudd, ACIM
About the Author

Article Tags

Biosimilars Funding Gene Therapy & ATMPs HTA PMA Trends Pricing

Share this article

Related articles

Articles
03.12.2025
Market Access & Pricing Trends for 2026

The Top Market Access Trends for 2026 The market access trends 2026 are being shaped by increasing g...

Read more
News
03.12.2025
Joint Scientific Consultations 2026 – key dates ...

The HTA Coordination Group (HTACG) has now confirmed the 2026 request periods for joint scientific c...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch